Trevi Therapeutics (TRVI) Stock: Buy, Sell, or Hold?
TRVI - Trevi Therapeutics, Inc. Common Stock
$13.91
-0.27 (-1.90%)
▼
5d:
-3.47%
30d:
-18.42%
90d:
-22.51%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 29, 2026 at $14.56 · last confirmed Sep 29, 2026
Strength: 5.0/10
Get Alerted When TRVI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TRVI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TRVI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TRVI is currently trading at $13.91, which is considered oversold relative to its 30-day fair value range of $14.55 to $17.14.
Technical Outlook: Technically, TRVI is in a uptrend. The price is currently testing key support at $13.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TRVI scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $28.18 (+102.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TRVI is in a uptrend. The price is currently testing key support at $13.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TRVI scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $28.18 (+102.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.55 -
$17.14
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
Protect Your Profits
Holding TRVI? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 102.6% below Wall St target ($28.18)
- CAUTION: Bottoming setup, but lagging the sector by 33% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$14.55 -
$17.14
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$13.72
Resistance Level
$15.27
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-24.11
Wall Street Target
$28.18
(+102.6%)
Share & Embed Analysis
Last updated: October 02, 2026 9:38 PM ET
Data refreshes hourly during market hours. Next update: 10:38 PM
Data refreshes hourly during market hours. Next update: 10:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRVI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 52 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$118 | 55 HOLD |
Advanced TRVI Option Strategies
Professional options setups generated by AI based on today's TRVI price and gamma walls.
